Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 3:12:829693.
doi: 10.3389/fonc.2022.829693. eCollection 2022.

Real-World First-Line Treatment Patterns and Outcomes in Hormone Receptor-Positive Advanced Breast Cancer Patients: A Multicenter, Retrospective Study in China

Zhanhong Chen  1 , Quchang Ouyang  2 , Yongsheng Wang  3 , Junsheng Wang  4 , Haixue Wang  5 , Xiaohong Wu  6 , Peili Zhang  7 , Jian Huang  1 , Yabing Zheng  1 , Wenming Cao  1 , Xiying Shao  1 , Ning Xie  2 , Can Tian  2 , Hao Liang  5 , Cailing Wang  4 , Ying Zhang  6 , Dianquan Ren  7 , Xiaojia Wang  1
Affiliations

Real-World First-Line Treatment Patterns and Outcomes in Hormone Receptor-Positive Advanced Breast Cancer Patients: A Multicenter, Retrospective Study in China

Zhanhong Chen et al. Front Oncol. .

Abstract

Background: Recent data on first-line treatment patterns administered to hormone receptor-positive (HR+) advanced breast cancer (ABC) patients in the real-world setting are limited. This study aimed to report the first-line treatment patterns and outcomes of HR+ ABC patients in China.

Methods: This was a multicenter, noninterventional study. Eligible patients were cytologically or histologically confirmed to have HR+ ABC with ≥2 complete medical records and received first-line therapies between January 2015 and June 2019. Treatment patterns and outcomes were extracted from structured or unstructured electronic medical records. Progression-free survival (PFS) was analyzed with the Kaplan-Meier method.

Results: In total, 1072 patients with HR+ ABC were enrolled at 6 treatment sites: 327 human epidermal growth factor receptor 2-positive (HER2+) patients, 696 HER2-negative (HER2-) patients and 49 HER2-unknown patients. Overall, 62.41% of patients received first-line chemotherapy (CT), 21.08% received targeted therapy (TT) and 15.49% received endocrine therapy (ET). For HR+/HER2+ patients, 65.14% received TT, 28.44% received CT, and 5.81% received ET. Compared with patients who received TT, patients who received CT alone, had a significantly worse median PFS (adjusted hazard ratio [HR] =2.59, 95% confidence interval [CI], 1.64-4.10, p<0.001). For HR+/HER2- patients, 77.01% received CT, 20.69% received ET and 1.15% received TT. Compared with patients who received ET, patients who received CT with maintenance therapy had a significantly prolonged median PFS (adjusted HR =0.57, 95% CI, 0.44-0.76, p<0.001). Among HR+/HER2- patients who received CT with maintenance treatment, those with maintenance ET had a longer median PFS than those with maintenance CT, but the difference was not significant (adjusted HR=0.92, 95% CI, 0.64-1.33, p=0.66).

Conclusions: This real-world study demonstrates that CT remains the mainstream first-line treatment option for HR+ patients in China. Among patients with HR+/HER2+ ABC, the majority received first-line TT and experienced a PFS benefit. A high percentage of HR+/HER2- patients received CT as first-line therapy in clinical practice. PFS benefit was significantly longer in patients who received CT with maintenance therapy. Moreover, there was no obvious difference in PFS between maintenance ET and CT. Maintenance ET may be a better choice considering its lower toxicity and better quality of life.

Keywords: advanced breast cancer; first-line treatment; hormone receptor-positive; outcomes; real-world study.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Reviewers ZY and YS declared a past co-authorship with one of the authors QO to the handling editor.

Figures

Figure 1
Figure 1
Kaplan-Meier curves of progression free survival among HER2+, HER2-, and HER2-unknown groups.
Figure 2
Figure 2
Kaplan-Meier curves of progression free survival of HR+/HER2+ patients. CT, chemotherapy; MT, maintenance therapy; ET, endocrine therapy; TT, targeted therapy.
Figure 3
Figure 3
Kaplan-Meier curves of progression free survival of HR+/HER2- patients. CT, chemotherapy; MT, maintenance therapy; ET, endocrine therapy.
Figure 4
Figure 4
Kaplan-Meier curves of progression free survival of HR+/HER2- patients between maintenance therapies. CT, chemotherapy; ET, endocrine therapy.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast Cancer. Lancet (2021) 4:S0140-6736(20)32381-3. doi: 10.1016/S0140-6736(20)32381-3. - DOI - PubMed
    1. Feng RM, Zong YN, Cao SM, Xu RH. Current Cancer Situation in China: Good or Bad News From the 2018 Global Cancer Statistics? Cancer Commun (2019) 39(1):22. doi: 10.1186/s40880-019-0368-6 - DOI - PMC - PubMed
    1. Fan L, Strasser-Weippl K, Li J, St Louis J, Finkelstein DM, Yu KD, et al. . Breast Cancer in China. Lancet Oncol (2014) 15(7):e279–89. doi: 10.1016/S1470-2045(13)70567-9 - DOI - PubMed
    1. Yap YS, Lu YS, Tamura K, Lee JE, Ko EY, Park YH, et al. . Insights Into Breast Cancer in the East vs the West: A Review. JAMA Oncol (2019) 5(10):1489–96. doi: 10.1001/jamaoncol.2019.0620 - DOI - PubMed
    1. Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, et al. . 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†. Ann Oncol (2018) 29:1634–57. doi: 10.1093/annonc/mdy192 - DOI - PMC - PubMed